8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Sep 22, 2022)

Filed September 22, 2022For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC), also known as BeiGene, Ltd., reported significant regulatory developments in Europe on September 19th and 20th, 2022. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval for BRUKINSA® (zanubrutinib) in the treatment of adult patients with marginal zone lymphoma (MZL) who have undergone at least one prior anti-CD20 therapy. Furthermore, the National Institute for Health and Care Excellence (NICE) in England issued a final appraisal document recommending BRUKINSA® for adult patients with Waldenström's Macroglobulinemia (WM) who have received at least one prior treatment, under specific conditions where bendamustine plus rituximab is also deemed suitable. These positive regulatory milestones in key European markets represent substantial progress for BRUKINSA®'s market access and potential commercialization.

Key Highlights

  • 1European Medicines Agency (EMA) CHMP issues positive opinion for BRUKINSA® (zanubrutinib) for Marginal Zone Lymphoma (MZL).
  • 2BRUKINSA® recommended for adult MZL patients who have received at least one prior anti-CD20-based therapy.
  • 3National Institute for Health and Care Excellence (NICE) recommends BRUKINSA® for Waldenström's Macroglobulinemia (WM) in adults.
  • 4NICE recommendation for WM is for patients with at least one prior treatment and contingent on bendamustine plus rituximab suitability.
  • 5These announcements indicate positive steps towards market access and potential reimbursement for BRUKINSA® in Europe.
  • 6The filing incorporates two press releases detailing these regulatory achievements.

Frequently Asked Questions

The positive opinion from the CHMP is a crucial step towards the formal approval of BRUKINSA® by the European Medicines Agency for the treatment of adult patients with marginal zone lymphoma. This indicates that regulatory experts believe the drug meets the required standards for safety and efficacy in this indication.

The NICE recommendation is conditional. It applies to adult patients with Waldenström's Macroglobulinemia who have received at least one prior treatment, but only if bendamustine plus rituximab is also considered a suitable treatment option for the patient.

This filing highlights two specific indications for BRUKINSA®: the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy, and the treatment of adult patients with Waldenström's Macroglobulinemia who have had at least one treatment.

No, this 8-K filing focuses solely on other events, specifically regulatory updates regarding BRUKINSA®. It does not contain any new financial statements or updates on the company's financial performance.